<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90841">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044653</url>
  </required_header>
  <id_info>
    <org_study_id>GX-E2(EPO-hyFc)_P2</org_study_id>
    <nct_id>NCT02044653</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)</brief_title>
  <official_title>Phase II Clinical Trial to Explore the Optimal Fixed Starting Dose &amp; Dosing Interval and to Evaluate the Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease and Receiving Hemodialysis (HD) / Peritoneal Dialysis (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of study is

        -  Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2

        -  Part B : To evaluate the proof of concept (POC) of GX-E2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective of study is to evaluate:

        -  change of red blood cell indices in anemic patients with chronic kidney disease
           receiving hemodialysis/peritoneal dialysis when administering GX-E2
           intravenously/subcutaneously

        -  change of reticulocyte indices in anemic patients with chronic kidney disease receiving
           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously

        -  safety of GX-E2 when administering intravenously/subcutaneously

        -  incidence of blood transfusion in anemic patients with chronic kidney disease receiving
           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously

        -  Immunogenicity in anemic patients with chronic kidney disease receiving
           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>average change of Hemoglobin level</measure>
    <time_frame>change from baseline in Hemoglobin level at 6 weeks (part A) &amp; 14 weeks (part B)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of red blood cell indices</measure>
    <time_frame>change from baseline in red blood cell indices at 6 weeks(part A) &amp; 14 weeks (part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of reticulocyte indices</measure>
    <time_frame>change from baseline in reticulocyte indices at 6 weeks (part A) &amp; 14 weeks (part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence, degree, outcome of adverse event</measure>
    <time_frame>during 6 weeks of study period (part A) &amp; 14 weeks of study period (part B)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence, frequency, amount of blood transfusion</measure>
    <time_frame>during 6 weeks of study period (part A) &amp; 14 weeks of study period (part B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity: ratio of neutralizing antibody &amp; binding antibody in subjects</measure>
    <time_frame>comparison from pre-treatment to post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Group A (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Among Arm groups in Part A, 4 optimal doses will be selected and used as Arm group in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L (Part B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of NESP (Aranesp) at dose of 30 ug every week
subcutaneous administration of NESP (Aranesp) at dose of 30 ug every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-E2</intervention_name>
    <description>Each Group hemodialysis patients (n=10) will be administered GX-E2 5ug/kg to 8ug/kg</description>
    <arm_group_label>Group A (Part A)</arm_group_label>
    <arm_group_label>Group B (Part A)</arm_group_label>
    <arm_group_label>Group C (Part A)</arm_group_label>
    <arm_group_label>Group D (Part A)</arm_group_label>
    <other_name>GC1113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-E2</intervention_name>
    <description>Each Group Peritoneal dialysis (n=10) will be administered GX-E2 3ug/kg to 8ug/kg</description>
    <arm_group_label>Group E (Part A)</arm_group_label>
    <arm_group_label>Group F (Part A)</arm_group_label>
    <arm_group_label>Group G (Part A)</arm_group_label>
    <arm_group_label>Group H (Part A)</arm_group_label>
    <arm_group_label>Group I (Part A)</arm_group_label>
    <arm_group_label>Group J (Part A)</arm_group_label>
    <other_name>GC1113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-E2</intervention_name>
    <description>Each Group Hemodialysis (n=25) and Peritoneal dialysis (n=25) will be administered GX-E2 3ug/kg to 8ug/kg</description>
    <arm_group_label>Group K (Part B)</arm_group_label>
    <other_name>GC1113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NESP (Aranesp)</intervention_name>
    <description>Each Group Hemodialysis (n=25) and Peritoneal dialysis (n=25) will be administered NESP 30ug</description>
    <arm_group_label>Group L (Part B)</arm_group_label>
    <other_name>Aranesp</other_name>
    <other_name>Darbepoetin alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  ≥18 yr of age

          -  Chronic Kidney diseases with hemodialysis, peritoneal dialysis

          -  Adequate transferrin saturation (≥20%), serum ferritin (≥100g/dl)

          -  Should have received Vitamine B12 ≥ 3 months before the first dose of study agent

          -  Should have received Folate  ≥3 months before the first dose of study agent

          -  No erythropoietin (EPO) therapy within 2month before the planned first dose of GX-E2
             and Hb&lt;10g/dL or No EPO therapy within month before the planned first dose of GX-E2
             and Hb&lt;10g/dL

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Uncontrolled arrhythmia

          -  History of acute or chronic bronchospastic disease (including asthma and  chronic
             obstructive pulmonary disease)

          -  History of hypersensitivity to the study drug or to similar drug

          -  aspartate aminotransferase/alanine aminotransferase (ALT/AST) &gt; 3 times Upper Normal
             Limit of Normal (UNL)

          -  Absolute neutrophil count ≤ 1,500 per microliter (uL)

          -  Donation or loss of ≥400 milliliter (mL) of blood within 8 weeks prior to first dose

          -  Major surgery within 3 months

          -  Grand Mal epilepsy

          -  History of drug or alcohol abuse in the 6 months prior to Screening

          -  Participation in any clinical investigation in the 4 week period prior to dosing

          -  Refractory of erythropoiesis stimulating agent (ESA) treatment

          -  Systemic hematologic diseases (e.g. Pure red cell anemia, sickle cell anemia,
             myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Woo Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>222 Banpo-daero,Seocho-gu,Seoul 137-701 Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St.Mary'S Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang Chul-Woo, Director</last_name>
      <phone>82-2-2258-6851</phone>
      <email>yangch@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yang Chul-Woo, Director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
